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Abstract 
Transforming growth factor beta (TGFβ) is a cytokine that regulates cellular adhesion, 
proliferation and apoptosis. In the context of cancer, TGFβ induces processes such as 
epithelial-to-mesenchymal transition (EMT).  More recently, TGFβ has been discovered to 
also induce autophagy, and the relationship between TGFβ-induced EMT and autophagy 
remains unknown. Due to its involvement in autophagy and its established interactions with 
key TGFβ signaling proteins, this thesis focuses on the sequestosome 1 (p62/SQSTM1) 
protein.  Here, I have shown that p62/SQSTM1 co-localizes with TGFβ receptors at the same 
time point that the receptors localize to Rab7-positive late endosomes. siRNA-mediated 
silencing of p62/SQSTM1 was also observed to prime non-small cell lung cancer cells to 
undergo an E-cadherin to N-cadherin shift, but this is not due to alterations of canonical 
TGFβ signaling. Furthermore, TGFβ induces a loss in nuclear p62 protein levels and 
sustained TGFβ incubation reduces total p62 levels, while converting light chain 3 beta 
(LC3B) I to LC3BII (a process that is a marker of autophagy). Finally, TGFβ-induced EMT 
and autophagy was shown to be dependent on the presence of the p62/SQSTM1-interacting 
proteins, TRAF6 and aPKC.  Taken together, these findings provide new insight into the role 
of p62 in TGFβ signaling and autophagy, as well as provide possible relationships between 
EMT and autophagic processes. 
Keywords 
Autophagy, transforming growth factor beta (TGFβ), p62/SQSTM1, epithelial-to-
mesenchymal transition (EMT), cancer, atypical protein kinase C (aPKC), Tumor necrosis 
factor-associating factor 6 (TRAF6), Smad signalling
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Chapter 1 : Introduction 
 Lung Cancer 1.1.
Cancer is the leading cause of death in Canada, claiming more lives than heart disease, 
accidents, and suicide combined (Canadian Cancer Society, 2017). Lung cancer in 
particular is responsible for the highest number of cancer deaths in the country, causing 
an estimated 21 000 deaths annually (Canadian Cancer Society, 2017). 
There are two major types of lung cancer: small cell lung cancer and non-small cell lung 
cancer (NSCLC). Of the two types, NSCLC is slower growing than its counterpart, 
however, it is less responsive to treatment and also more prevalent— it constitutes 80-
85% of lung cancer diagnoses (CancerCare, 2017). The NSCLC group consists of 
adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and other subtypes. 
Adenocarcinoma is the most common of the NSCLCs and it usually originates from 
glandular cells found on the lung periphery. It is also the most common type of lung 
cancer in smokers and non-smokers alike (American Cancer Society Inc., 2017). 
As with many epithelial tumors, malignancies in the lung may also possess the potential 
to migrate to other parts of the body and establish secondary tumors. This occurrence, 
called metastasis, involves several stages including invasion and intravasation into the 
lymph or bloodstream, extravasation, and colonization (as reviewed in Nguyen et al., 
2009). It is of great importance to define this process, as 90% of cancer-related deaths are 
attributed to the establishment of metastatic lesions, as opposed to the primary tumor 
(Beck et al., 2014).  
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 The TGFβ signaling pathway 1.2.
1.2.1. TGFβ as both a tumor suppressor and a tumor promoter 
The transforming growth factor beta (TGFβ) pathway is a critical regulator of many 
physiological processes including cell growth, morphogenesis, proliferation and 
apoptosis (Horbelt et al., 2012; Massague, 2012). Normally, TGFβ signaling acts to 
suppress tumor growth and cell proliferation. These processes are controlled by canonical 
TGFβ signaling through regulation of cytostatic genes. For example, TGFβ induces the 
expression of cyclin dependent kinase inhibitors such as p21CIP1 and p15INK4B  in neuronal 
and epithelial cells (Elliott & Blobe, 2005; Padua & Massagué, 2009), which inhibits the 
progression of the cell cycle from the G1 to S phase. Similarly, p57 is induced by TGFβ 
in haematapoietic cells to attenuate cell growth (Meulmeester & Ten Dijke, 2011). In 
addition to cell dependent kinases, TGFβ also suppresses the transcription factor c-Myc, 
which is a known oncogene that promotes cell growth (Zhang, 2009; Meulmeester & Ten 
Dijke, 2011). Thus, TGFβ is important in preventing uncontrolled cell proliferation. 
Aberrant TGFβ signaling is implicated in the development of cardiovascular diseases, 
fibrodysplasia, and several types of cancer (Kang et al., 2009; Horbelt et al., 2012). 
Indeed, dysregulation of the TGFβ pathway has been found to be involved in the 
development of breast, colorectal, pancreatic and lung tumors (Elliott & Blobe, 2005; 
Horbelt et al., 2012).   
In order for cells to become malignant, they must evade the tumor suppressive effects of 
TGFβ. This can occur in one of two ways: silencing TGFβ signaling altogether by 
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disrupting key components in the pathway, or exclusively repressing the branch of TGFβ 
signaling that suppresses tumor progression. The second of these mechanisms allows the 
tumor cells to then exploit the residual functional TGFβ signaling towards growth and 
invasion processes (Meulmeester & Ten Dijke, 2011; Massague, 2012). Thus, whether 
TGFβ acts as a tumor suppressor versus a tumor promoter is heavily dependent on 
context.  
1.2.2. TGFβ and lung cancer 
In the majority of pancreatic and colon cancers, the first of the aforementioned 
mechanisms is used to evade the tumor suppressive effects of TGFβ (Massagué, 2008). 
This type of TGFβ resistance is well defined. However, in other cancers such as those 
found in the lung, mechanisms used to select for and bypass tumor suppressive TGFβ 
pathways are poorly understood. In addition, the method by which these tumors shift to 
benefit from remaining TGFβ signaling has yet to be elucidated (Elliott & Blobe, 2005).  
It is clear that lung cancer cells take advantage of TGFβ signaling: lung tumors 
overexpress TGFβ ligand, and a high serum level of TGFβ in adenocarcinoma patients 
has been shown to be correlated with poor prognosis (Elliott & Blobe, 2005; Xue et al., 
2016). Furthermore, these studies have also suggested that higher levels of TGFβ in these 
patients were involved in the progression of tumor angiogenesis and metastasis (Jeon & 
Jen, 2010).   
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1.2.3. Ligands and receptors of the TGFβ superfamily 
The ligands of the TGFβ superfamily can be divided into a TGFβ branch and a BMP 
branch (Fig 1.1A). Though structurally similar to the TGFβ subfamily, BMP ligands 
regulate osteogenesis, neurogenesis and developmental processes (Drabsch & Dijke, 
2012). In contrast, ligands of the TGFβ subfamily are more involved in proliferation and 
apoptosis. Six isoforms of TGFβ ligand exist, however, mammals only express three: 
TGFβ1, TGFβ2, and TGFβ3. The first of these isoforms is most abundant in the body, 
and was the first to be discovered in 1983, having been observed to promote rat fibroblast 
growth (Drabsch & Dijke, 2012).   
As a cytokine, TGFβ1 is produced by a variety of cells and tissues in the body. Its 
precursor polypeptide is 390 amino acids in length and it is glycosylated after 
transcription (Katz et al., 2013). Thereafter, two precursors dimerize via disulfide linkage 
to form an inactive homodimer, which is then secreted out of the cell (Annes et al., 2003; 
Kang et al., 2009). This latent form of TGFβ1 binds extracellular proteins until 
proteolytic cleavage and separation from the propeptide converts the ligand into its 
mature and active form (Annes et al., 2003). Normal serum levels of TGFβ1 in a healthy 
individual are found to be in the lower picomolar range (Kong et al., 1995; Tas et al., 
2014), and the largest source of ligand production is from blood platelets. Upon injury, 
platelets release more TGFβ in order to control the inflammation, regeneration, and 
proliferation of cells (Massague, 2012). Tumors are also an abundant source of TGFβ. 
Although initially released to impede the progression of potentially malignant cells, 
TGFβ is also released by tumors to benefit their growth (Katz et al., 2013).  
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Figure 1.1. Overview of TGFβ signaling 
(A) Different ligands of the TGFβ family, their respective receptors, and associated 
downstream signaling proteins, termed Smads. (B) Signaling by TGFβ1 occurs when 
dimerized ligand binds the type II receptor, which then phosphorylates and binds the type 
I receptor to form an activated heterocomplex. Canonical signaling involves the 
phosphorylation and nuclear translocation of Smads, which associate with co-factors to 
modulate gene transcription. Non-canonical TGFβ pathways include signaling through 
the TRAF6-TAK1-MKK-p38 and Par6/aPKC pathways. (C) Receptor trafficking via 
clathrin and caveolin coated pits promotes signaling and degradation, respectively.  
Acronyms: transforming growth factor beta (TGFβ), transforming growth factor beta 
receptor (TβR), bone morphogenic protein (BMP), bone morphogenic protein receptor 
(BMPR), activin receptor (ActR), anti-mullerian hormone/mullerian inhibiting substance 
(AMH/MIS), anti-mullerian hormone receptor (AMHR), growth differentiation factor 
(GDF), activin-like receptor kinase (ALK), Small phenotype mothers against 
decapentaplegic homolog (Smad), Smad anchor for receptor activation (SARA), atypical 
protein kinase C (aPKC), TNF receptor-associated factor 6 (TRAF6), transforming 
growth factor beta-activated kinase 1 (TAK1), mitogen-activated protein kinase kinase 
(MKK) partitioning defective 6 (Par6), Smad ubiquitin regulatory factor (Smurf). 
7 
 
Much like the ligands of the TGFβ superfamily, the type I and type II receptors can also 
be grouped into either the TGFβ or BMP subfamily. In humans, there are seven type I 
and five type II receptors, which assemble in different combinations as determined by the 
ligand (Fig 1.1A). TGFβ isoforms only bind one type of type II receptor, the 
constitutively active TGFβ receptor II (TβRII), which then also exclusively binds one 
type of type I receptor, TGFβ receptor I (TβRI, also called activin-like kinase 5; ALK5) 
(Drabsch & Dijke, 2012; Cantelli et al., 2016). A third type of receptor is also known to 
interact with TGFβ—the co-receptor known as TGFβ receptor III (TβRIII).  This co-
receptor can modulate the access of the type II receptor to different TGFβ isoforms by 
interacting with them, but TβRIII is not directly involved in signaling (Katz et al., 2013). 
1.2.4. TGFβ signaling 
Activation of classical TGFβ signaling occurs when ligand binds to the extracellular 
portion of a transmembrane type II receptor (Fig. 1.1B). The type II receptor then binds a 
type I receptor to form an activated heterotetrameric complex (composed of dimerized 
ligand, type II and type I receptors) that can activate several downstream pathways due to 
its serine/threonine kinase activity (Wrana et al., 1992). The canonical downstream 
effectors of the type I receptor are intracellular receptor-regulated Smads (R-Smads). The 
receptor complexes initiated by TGFβ and BMP cytokines activate Smads 2/3 and Smads 
1/5/8, respectively, through phosphorylation. For TGFβ ligands, this phosphorylation 
occurs at two serine residues near the C-terminus of Smads 2/3. These activated R-Smads 
then leave the receptors to associate with Smad4, and the heteromeric Smad complex is 
then translocated to the nucleus. The accumulation of these nuclear Smads stimulate the 
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recruitment of various transcriptional cofactors, as well as alterations in gene 
transcription (Padua & Massagué, 2009). Some examples of transcription factors 
regulated by Smads are p300, p107, CBP, Swift, Snail and Twist, and downstream gene 
regulation includes that of c-Myc, osteocalcin, and E-Cadherin (Massagué et al., 2005; 
Heldin et al., 2012). There also exists a cell-dependent factor that is important for 
determining which transcription factors are recruited, and how gene expression is 
regulated (for example, the amounts of certain available transcription factors to be 
recruited) (Massagué et al., 2005). 
There are also a number of atypical, non-Smad pathways through which TGFβ can signal 
(Fig. 1.1B). These include the activation of Par6-RhoA, TRAF6-TAK1-p38/JNK, and 
PI3K-Akt-mTOR pathways (Zhang, 2009; Meulmeester & Ten Dijke, 2011; Pickup et 
al., 2013). Interestingly, recent findings have shown that atypical protein kinase C 
(aPKC) is involved in both the canonical Smad-dependent pathway and atypical Par6 
pathways of TGFβ (Gunaratne et al., 2015).  
1.2.5. SMAD proteins 
TGFβ signaling mobilizes Smad proteins, which are transcription factors capable of 
regulating hundreds of genes at once. Eight Smads exist in humans, and they can be 
grouped into three categories: receptor-regulated Smads (R-Smads), Co-operating Smads 
(Co-Smads) and Inhibitory Smads (I-Smads). Five Smads fall into the R-Smad category, 
Smads 1/2/3/5/8, and they are direct substrates of the TGFβ receptor superfamily 
(Drabsch & Dijke, 2012). Both the C-terminus and the N-terminus consist of Mad-
homology (MH) domains that are connected by a variable linker region (Massagué et al., 
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2005). The ability of R-Smads to bind to DNA is attributed to its N-terminal MH1 
domain, and the C-terminal MH2 domain allows R-Smads to bind other proteins (Horbelt 
et al., 2012). Prior to activation, R-Smads associate with proteins using its MH2 domain, 
and this sequesters and retains them to the cytoplasm until they are activated (Heldin & 
Moustakas, 2012).  In the case of Smads 2/3, an example of such a protein is Smad 
Anchor for Receptor Activation (SARA). Activation of Smads 2/3 occurs when SARA 
facilitates its phosphorylation on two carboxy-terminal serine residues by type I TGFβ 
receptors, which subsequently interrupts the SARA-Smad interaction. This separation 
allows Smads 2/3 to bind to the Co-Smad (Smad4) and also exposes a nuclear import 
signal to allow the translocation of the Smad complex (Padua & Massagué, 2009). Smad 
nuclear import involves the nuclear localization sequence of Smads 2/3 as well as the 
importin nuclear pore protein (Hill, 2009). Once inside the nucleus, the Smad complex 
binds a 5’-CAGAC-3’ DNA motif in partnership with other transcription factors to 
regulate the expression of hundreds of genes (Massague, 2012; Macias et al., 2016). This 
includes the upregulation in the expression of the I-Smads, which establishes a negative 
feedback loop (Drabsch & Dijke, 2012).  
Inhibitory I-Smads 6/7 bind to R-Smads in competition with TGFβ receptors (reviewed 
in Itoh et al., 2000). They down-regulate TGFβ signaling by recruiting E3 ubiquitin 
ligases, such as Smad ubiquitination regulatory factors (Smurfs) 1 and 2, that tag 
activated receptors to target them for proteasome-dependent degradation (Massagué et 
al., 2005). I-Smads promote the degradation of R-Smads in a similar manner by first 
recruiting phosphatases to deactivate them, and then recruiting ubiquitin ligases like 
Nedd4 (in the case of Smads 2/3) (Itoh et al., 2000; Heldin & Moustakas, 2012). Aside 
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from degradation, modification of the R-Smad linker region via phosphorylation can also 
regulate its activity (Schilling et al., 2006).  
In addition to propagating TGFβ signaling, Smads can also act to integrate TGFβ with 
other signaling pathways. Smad-enabled crosstalk with TGFβ includes the incorporation 
of the Wnt, Akt, and p38/MAPK pathways (Massagué et al., 2005; Leivonen & Kahari, 
2007).  
1.2.6. Receptor trafficking and internalization 
The method by which TGFβ receptors (TGFβRs) are trafficked and internalized can also 
regulate downstream signaling. TGFβR endocytosis can occur in two ways—through a 
clathrin-mediated pathway or a caveolin/lipid-raft pathway (Fig. 1.1C; Balogh et al., 
2013).  
The clathrin-mediated endocytosis of TβRII is constitutively active, and occurs when 
TβRII binds clathrin-coated pits. This process is mediated by the di-leucine motif found 
in the cytoplasmic domain of TβRII and is also dependent on the kinase activity of the 
type II—but not the type I—receptor (Anders et al., 1998; Kang et al., 2009). After 
internalization, the receptors are then found in early endosomes that are positive for 
markers Rab5 and early endosome antigen-1 (EEA1). In the absence of ligand, the 
receptors are then recycled back to the cell surface via Rab11 positive endosomes (Di 
Guglielmo et al., 2003; Chen, 2009).  If, however, there is ligand present, downstream 
signaling occurs at the early endosome for an extended period of time (Le Roy & Wrana, 
2005). Thereafter, the receptors are then sorted into either late endosomes (which destines 
11 
 
receptors to lysosomal degradation) or recycling Rab11 endosomes. The mechanism by 
which sorting occurs remains unknown (Chen, 2009).  
Clathrin-mediated endocytosis promotes robust canonical TGFβ signaling through Smads 
(Runyan et al., 2005). In contrast, caveolin-mediated endocytosis facilitates the 
degradation of receptors which attenuates downstream signaling (Di Guglielmo et al., 
2003; Kang et al., 2009). Thus, there is a balance in the proportion of receptors existing 
between the clathrin and caveolin compartments of the cell membrane, and it is an 
important regulator of signal transduction (Le Roy & Wrana, 2005). If receptors are 
shifted into lipid rafts, TβRI associates with caveolin-1, which inhibits downstream Smad 
signaling (Razani et al., 2001). Furthermore, the localization of Smad7 and Smurf 1/2 
proteins to caveolin vesicles is also proposed to promote the turnover of TGFβRs. 
 Epithelial-to-mesenchymal transition 1.3.
1.3.1. An introduction to EMT processes 
Epithelial-to-mesenchymal transition (EMT) occurs when epithelial cells begin to 
undergo biochemical changes that initiate the loss of epithelial traits in exchange for the 
adoption of a mesenchymal phenotype (Fig. 1.2). It is characterized by a loss in apical-
basal cell polarity and in the adhesion to the basement membrane, as well as the 
dissolution of cell-cell junctional complexes (Heldin et al., 2012). This is accompanied 
by an increase in matrix protease production, the remodeling of structural cell 
components (i.e. microtubules and microfilaments) and an enhancement in the cell’s  
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Figure 1.2. Epithelial-to-mesenchymal transition  
During EMT, cells lose their epithelial phenotype and then adopt a mesenchymal one. 
Features such as junctional complexes and cell-to-cell adhesion are lost, and the cell 
gains migratory capacity through this process. Cells that have undergone EMT have also 
been shown to be more resistant to apoptosis, and express markers such as N-cadherin, 
vimentin, and fibronectin.   
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resistance to apoptosis. At a molecular level, the transition of a cell from an epithelial to 
mesenchymal state can be followed with the use of protein markers. Epithelial cells 
express E-cadherin, occludins, claudins and cortical actin. These proteins maintain the 
adherens and tight junctions that are required for a tightly formed and organized layer of 
cells. This is in contrast to mesenchymal cell markers, which include N-cadherin, 
vimentin, fibronectin, and actin stress fibres (Lamouille et al., 2014). This expression 
profile supports the adhesion of mesenchymal cells to the extracellular matrix, as 
opposed to adhesion to other cells, and increases their migratory capacity (Miyazono, 
2009).   
There are three subtypes of EMT, each of which is defined by a different context and 
function (Miyazono et al., 2012). Type 1 EMT occurs during early development, which 
promotes the diversification of cells and supports gastrulation and thus, embryogenesis. 
Type 2 EMT is necessary for wound healing and tissue regeneration. In this context, 
EMT facilitates the formation of fibroblasts from secondary epithelial cells in response to 
inflammation and organ fibrosis. Type 3 EMT is a precursor process of metastasis and 
involves the development of migratory cells from tumorigenic epithelium (Kalluri & 
Weinberg, 2009). 
1.3.2. EMT and cancer 
Many hallmarks of the EMT process are associated with more aggressive and resistant 
tumors (reviewed in Ye & Weinberg, 2015). When epithelial cancer cells become 
mesenchymal, it allows them to undergo intravasation, which drives systemic 
dissemination (Kalluri & Weinberg, 2009). Similar to type 1 developmental EMT, the 
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upkeep of type 3 EMT programs relies on contextual signals from various locations in the 
body. Stromal cells are able to release a vast array of molecules that regulate EMT; these 
include Wnt, Notch, VEGF, and TGFβ (Ye & Weinberg, 2015). 
1.3.3. EMT and TGFβ 
Of the TGFβ isoforms, TGFβ2 and 3 play major roles in the progression of type 1 
developmental EMT. TGFβ2 is involved in the formation of atrioventricular cushions, 
and palate fusion requires an EMT program that is driven by TGFβ3 (Thiery, 2002). In 
comparison, TGFβ1 is involved in post-natal fibrosis, wound healing and cancer-related 
type 2 and 3 EMT. Its expression is elevated during kidney, hepatic, and pulmonary 
fibroses, which all have a preceding EMT event (Lamouille et al., 2014). The 
overexpression of TGFβ1 also activates EMT programs that develop invasive tumor cells 
(Miyazono, 2009).  
The activation of EMT in cancer cells by TGFβ is regulated at multiple levels. Both 
canonical and atypical TGFβ signaling not only modify transcriptional regulation and 
gene expression, but they also involve alternative splicing, epigenetic changes, and 
miRNA mechanisms of control, which all contribute to the induction of EMT (reviewed 
in Katsuno et al., 2013).  
Within canonical TGFβ signaling, Smads directly enhance the expression of proteins, 
microRNAs and transcription factors. This includes the promotion of mesenchymal 
protein markers like vimentin and fibronectin (Lamouille et al., 2014) as well as the 
enhanced expression of microRNA miR-155, which aids in the dissolution of tight 
junctions (Kong et al., 2008). Transcription factors such as Snail, Slug, Twist, and Zeb 1 
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and 2, are also upregulated by Smad signaling. These factors are important for repressing 
E-cadherin expression, which is a critical step in the progression of EMT (Thiery, 2002). 
The expression of one factor can promote the expression of another, and partnerships also 
exist between them. For example, Snail can augment the expression of Twist, and 
together, Snail and Twist induce Zeb1 (Heldin et al., 2012). These interrelated 
transcription factors are also capable of indirectly supporting a mesenchymal phenotype. 
Alternative splicing of epithelial proteins occurs when Zeb 1 and 2 suppress the 
expression of certain RNA-binding proteins. Another example includes Snail-mediated 
epigenetic changes to epithelial genes, such as the methylation of the E-cadherin 
promoter, via interactions with methyl transferases (Katsuno et al., 2013).  
Non-canonical TGFβ pathways are also important regulators of EMT processes. The tight 
junction protein Par6 undergoes aPKC-dependent phosphorylation by TβRII (Gunaratne 
et al., 2013). This causes Par6 to then recruit Smurf1 to tag RhoA for degradation 
through ubiquitination (Ozdamar et al., 2005). Since it is a critical regulator of the 
cytoskeleton, degradation of RhoA elicits structural changes such as the disruption of 
tight junctions and loss of cell polarity (Ozdamar et al., 2005; Miyazono, 2009). Another 
atypical TGFβ pathway that contributes to EMT starts with the activation of TNF 
receptor-associated factor 6 (TRAF6), whose downstream effector is p38/MAPK. This 
signaling stabilizes Snail by inhibiting GSK3β, which leads to further repression of E-
cadherin (Lamouille et al., 2014).  
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 Autophagy 1.4.
Autophagy, Greek for “self-eating”, is a regulated process by which the cell can degrade, 
recycle, and repurpose its components. There are three types of autophagy, defined by the 
process by which cargo is delivered to the lysosome: macro-autophagy, micro-autophagy, 
and chaperone-mediated autophagy (Mizushima, 2007).  Macro-autophagy involves the 
formation of a double membrane vesicle called an autophagosome, which sequesters 
cargo and then merges with the lysosome (Tanida, 2011). In microautophagy, 
cytoplasmic structures are engulfed directly by the lysosomal membrane without the use 
of an intermediate vesicle (Eskelinen & Saftig, 2009). In chaperone-mediated autophagy, 
protein cargo forms a complex with chaperone proteins that is recognized by a receptor 
on the lysosomal membrane and then degraded after its translocation (Kaur & Debnath, 
2015). In contrast with the other two types of autophagy, chaperone-mediated autophagy 
is very selective and is not capable of initiating the degradation of larger cargoes, 
whereas both macro and micro autophagy are capable of being selective and non-
selective processes (Glick et al., 2010).  
Of all the types of autophagy, macro-autophagy (which will henceforth be referred to as 
“autophagy”) has been of most interest due to its involvement in metabolism, cell death, 
and immune response, which characterizes it as an significant process in maintaining 
homeostasis (Eskelinen & Saftig, 2009). Dysfunctional autophagic processes can lead to 
infectious, neurodegenerative, pulmonary, and vascular diseases, and it has also been 
shown to have an important role in the initiation, progression, and therapeutic resistance 
of cancer (Choi & Ryter, 2013).  
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1.4.1. The basics of autophagy induction 
Autophagy can be described to undergo six stages: initiation, nucleation, elongation, 
maturation, fusion, and degradation (Fig. 1.3A). In the initiation step, autophagic 
machinery found in the cytoplasm assembles into a scaffold complex that is essential for 
autophagy induction. These proteins include autophagy-related (Atg) proteins, such as 
Atg 13 and 101, which associate with UNC51-like kinase (ULK) 1 and FAK family 
kinase interacting protein of 200 kDa (FIP200). Together, these proteins form the ULK 
complex (Kaur & Debnath, 2015).  
During nucleation, an additional complex known as class III PI3K, (which includes 
Beclin 1, vacuolar protein sorting 15 [VPS15], VPS34 and ATG14) is recruited to the 
ULK complex (Tanida, 2011). This initiates the production of a phospholipid that is 
specific for the extension of a phagophore, which is an isolated lipid bilayer. In 
mammalian cells the origin of this membrane is still unclear, although it is suggested that 
trans-Golgi endosomes or the endoplasmic reticulum are probable sources (He & 
Klionsky, 2009). The elongation of this phagophore also requires the maturation of the 
lipidation of microtubule-associated protein light chain 3 (LC3B)-II (reviewed in Schaaf 
et al., 2017). Its original precursor, LC3B, is found in the cytosol and is cleaved by the 
cysteine protease, Atg4, upon autophagy induction. This then produces LC3B-I, which is 
activated by Atg7, then conjugated to phosphatidylethanolamine by Atg 3 to form LC3B-
II (Glick et al., 2010). Together with an Atg16-Atg12-Atg5 complex, LC3B-II facilitates 
the extension of the phagophore, such that the cytoplasmic cargo is engulfed (Farré & 
Subramani, 2016). The closure of the phagophore forms a double membrane organelle  
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Figure 1.3. 
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Figure 1.3. Autophagy induction and its role in cancer   
(A) Autophagy induction occurs in six phases: initiation, nucleation, elongation, 
maturation, degradation, and fusion. Initiation involves the formation of the ULK 
complex, which then localizes to the phagophore. More proteins are recruited during 
nucleation, and an Atg complex as well as the formation of LC3BII are required for the 
elongation of the phagophore around cargo that is targeted for autophagic degradation. 
Once the cargo is enclosed and the Atg complex dissociates, the autophagosome is 
considered mature. It then goes on to fuse with the lysosome, which contains hydrolases 
that degrade the engulfed autophagosome and its contents. (B) In early tumorigenesis, 
autophagy acts as a tumor suppressor by preventing the accumulation of cytotoxins. 
However, during tumor progression, autophagy can benefit cancer cells by supporting 
their survival and proliferation, especially in low-nutrient conditions.  
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called an autophagosome, and this maturation step also involves the dissociation of the 
Atg16-Atg12-Atg5 complex. LC3B-II, however, is bound to the autophagosome 
membrane and serves as a good marker for the induction of autophagy (Tanida, 2011). 
The outer membrane of the mature autophagosome then fuses to the lysosome, forming 
an autolysosome. The autophagic cargo is then degraded by lysosomal hydrolases 
(Levine et al., 2011). 
1.4.2. Autophagy and cancer 
Autophagy has several functions that allow it to act as both a tumor suppressor and a 
tumor promoter (Fig. 1.3B). First, autophagy acts to remove toxic waste products by 
degrading protein aggregates, and it also plays a major role in managing oxidative stress. 
In this manner, autophagy prevents tumorigenesis since it reduces the accumulation of 
potential mutagens (Choi & Ryter, 2013). Furthermore, autophagy has been shown to 
reduce inflammation and necrosis, both of which produce an environment conducive to 
cancer (Choi, 2012). There have also been studies showing more novel mechanisms of 
tumor suppression by autophagy. Young et al. (2009) observed that autophagy-deficient 
cells are able to avoid oncogene-induced senescence, a phenomenon in which potentially 
malignant cells stop dividing.  
It has not yet been shown that genetic silencing of core autophagy proteins promotes the 
formation of human cancers, however, this has been seen in mouse models (White, 
2015). For instance, a monoallelic deletion in the autophagy-dependent Beclin-1 gene 
promotes spontaneous tumorigenesis in the lungs and liver of mice (Eskelinen, 2011).  
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Once tumors are established, autophagy can also aid their survival, growth, and even 
therapeutic resistance (Kimmelman, 2011; White, 2015). Autophagy can also act as a 
tumor promoter since it provides an intracellular nutrient source. Due to the heterogeneity 
of tumors, some regions may not be as well vascularized and can even be hypoxic. In 
these areas, autophagy has been found to be up regulated in order to promote cell survival 
(Degenhardt et al., 2006).  
In cancer cell lines, autophagy has been shown to promote a tumorigenic process, as 
many cell lines express relatively high levels of autophagy at rest even in the absence of 
metabolic stress (White et al., 2015).  Furthermore, the survival of these cell lines can be 
reduced by the knockdown of core autophagic genes. This also holds true in genetically 
modified mouse models—Atg7-/- Kras-induced lung tumors were less proliferative when 
compared to control. They were also more sensitive to starvation due to the accumulation 
of lipids and defective mitochondria (Amaravadi et al., 2016).  
1.4.3. TGFβ-induced autophagy 
In a study done by Kiyono et al. (2009), TGFβ1 ligand was shown to be an inducer of 
autophagy in hepatocarcinoma and breast cancer cells. This activation was observed to be 
dependent on both canonical and atypical TGFβ signaling pathways, which then up 
regulate the expression of autophagic genes such as Beclin-1, Atg5 and Atg7 (Suzuki et 
al., 2010). Recent studies also suggest the involvement of the Disabled-2 (Dab2) 
endocytic adaptor protein in the regulation of autophagy by TGFβ (Jiang et al., 2016).  
Due to its recent discovery, much is still unknown about TGFβ-induced autophagy and 
its relation to other TGFβ-regulated processes such as EMT.  
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 p62: a multifunctional protein 1.5.
Selective autophagy occurs when specific cargo is targeted for degradation by the 
autolysosome. In order for this to occur, adaptor proteins like p62 (also known as 
sequestosome-1, SQSTM1) are required to sequester the cargo to the autophagosome 
(Farré & Subramani, 2016). Though many scaffolding proteins exist, p62 was the first 
autophagy adaptor to be identified. It is unique since, unlike the other adaptor proteins, 
p62 is able to regulate signaling by interacting with key pathway components (Moscat et 
al., 2016). 
1.5.1. Structure of p62 
The SQSTM1 gene is on chromosome 5g35 in humans, and it encodes the p62 protein 
that is 440 amino acids in length. It is highly conserved and homologues of SQSTM1 
exist in a variety of vertebrates (Bitto et al., 2014). Its transcription is up regulated by 
factors such as Nrf2, IL-3, and calcium (Puissant et al., 2012), and once translated and 
modified, p62 is distributed in numerous compartments of the cell, including the 
cytoplasm, nucleus, late endosomes, autophagosomes, and lysosomes (Sanchez et al., 
1998; Katsuragi et al., 2015).  
The different domains of p62 are what enable it to act as a multifunctional protein (Fig. 
1.4A). From the N-terminus to the C-terminus, p62 contains a Phox1 and Bem1p (PB1) 
domain, a zinc finger domain (ZZ), a TRAF6 binding domain (TB), an LC3-interacting 
region (LIR), a Keap1 interacting region (KIR), and a ubiquitin-associated domain 
(UBA). It also has 2 nuclear localization sequences (NLS) that flank the TB  
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Figure 1.4. p62: a multifunctional protein in autophagy 
(A) The structural domains of p62 include the Phox-BEM1 (PB1), zinc finger (ZZ), 
TRAF6 binding (TB), LC3 interacting region (LIR), Keap1 interacting region (KIR) and 
ubiquitin associated (UBA) region. p62 also has two nuclear localization signals that 
flank the TB domain and one nuclear export signal. (B) The various domains of p62 
enable it to function in numerous cell processes, such as autophagy, and signaling 
pathways, such as mTORC1, Nrf2, and NFκB. In autophagy, p62 selectively targets 
cargo for degradation and scaffolds it to the autophagosome via interaction with LC3BII. 
In signaling, p62 scaffolds and sequesters key protein players, which changes the 
outcome of certain pathways.   
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domain and a nuclear export signal just downstream of the second NLS (Katsuragi et al., 
2015).  
1.5.2. p62 and its role in autophagy   
As mentioned above, p62 facilitates selective degradation of mitochondria, microbes, and 
protein aggregates by autophagy (Fig. 1.4B). p62 is first phosphorylated by ULK1 at 
Ser407 in its UBA domain (Lim et al., 2015). Then, the selected cargo associates with 
p62 by either the UBA domain or PB1 domain for ubiquitinated or non-ubiquitinated 
cargo, respectively. In the case of ubiquitinated cargo, binding with p62 can be enhanced 
by phosphorylation on Ser403 in the UBA domain of p62 (Matsumoto et al., 2011). Next, 
p62 then undergoes self-oligomerization using its Phox-Bem1 (PB1) domain in order to 
effectively package and deliver the cargo to the phagophore (Puissant et al., 2012). The 
oligomerization step is crucial for mediating successful degradation by autophagosomes 
(Komatsu & Ichimura, 2010).  
The p62 oligomeric complexes then interact with the phagophore using its LIR domain. 
This region of p62 contains acidic and hydrophobic clusters, which can associate with 
several sites of LC3B-II, including two hydrophobic pockets and N-terminal basic 
residues (Katsuragi et al., 2015). Hydrolases in the autolysosome degrade both the cargo 
as well as p62, as both proteins are engulfed and localized to the autophagosome. Thus, 
the accumulation of p62 can serve as a marker for defective autophagy (Puissant et al., 
2012).  
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1.5.3.  p62 and its role in signalling 
Alongside autophagy, p62 has been shown to regulate signaling, despite having no 
catalytic abilities. Although it does not participate in any signaling cascades such as 
phosphorylation, p62 is able to regulate signaling by scaffolding important signaling 
components. It has been shown to act as a signaling hub in the mTORC1, NFκB, and 
Nrf2 pathways (Fig. 1.4B; Bitto et al., 2014; Katsuragi et al., 2015).  
When the level of amino acids is elevated, the mTORC1 pathway is activated in order to 
manage protein synthesis.  The amino acid sensing component, Rag GTPase, is able to 
associate with a subunit of the mTORC1 complex, Raptor, in a p62-dependent manner. 
Furthermore, p62 is necessary to initiate the auto-ubiquitination of TRAF6 (an E3 
ubiquitin ligase), which allows it to then ubiquitinate mTOR and enhance its activation of 
mTORC1 (Katsuragi et al., 2015). This results in the down regulation of autophagic 
processes, and the upregulation of cell growth (Levine et al., 2011; Puissant et al., 2012).  
The NFκB transcription factors regulate cell processes such as survival and 
differentiation once they are translocated to the nucleus (Moscat et al., 2007). Its nuclear 
import is regulated by a protein complex, consisting of aPKC (PKC iota and zeta), 
TRAF6, and receptor interacting protein (RIP) (Puissant et al., 2012). p62 is able to bind 
to each of these components, and scaffold them together to induce NFκB translocation. 
Using its PB1, TB, and ZZ domains, p62 associates with aPKC, TRAF6, and RIP, 
respectively (Katsuragi et al., 2015). Downstream effects of the NFκB pathway include 
the production of reactive oxygen species (ROS) scavengers and the induction of 
inflammatory response genes (Moscat et al., 2016). A positive feedback loop is also 
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established since p62 is also up regulated in response to NFκB, and this sustains NFκB 
signaling (Moscat & Diaz-Meco, 2012).  
Another pathway that helps to control oxidative stress is the Nrf2 pathway. Nrf2 is a 
transcription factor that is sequestered to the cytoplasm by a protein called Keap1. The 
non-covalent interaction between Nrf2 and Keap1 inhibits the activity of Nrf2 (Puissant 
et al., 2012). This is abrogated when p62 competitively binds Keap1 and targets it for 
degradation via selective autophagy using its KIR domain (Katsuragi et al., 2015). Nrf2 
is then activated and able to induce the transcription of genes such as those involved in 
detoxification, repair, and ROS scavenging (Bitto et al., 2014). Similarly to NFκB, Nrf2 
also sustains its signaling when establishing positive feedback by up regulating p62 
expression (Puissant et al., 2012). 
1.5.4. p62 and cancer 
Due to its role in autophagy and various signaling pathways, p62 is undoubtedly an 
important regulator of cancer-relevant processes. Its involvement in both tumor 
promoting and tumor suppressive mechanisms necessitates that the effects of p62 are 
heavily context-dependent. For example, studies done by and reviewed in Moscat et al., 
2016 reveal that p62 promotes tumorigenesis in hepatocarcinoma cells, but prevents 
cancer progression when expressed in the hepatostellate cells (tumor stromal fibroblasts). 
Thus, current studies are focused on discovering the consequences of p62 expression in a 
variety of contexts.  
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 Rationale and hypothesis   1.6.
In recent studies, it has been shown that sustained TGFβ signaling can induce autophagy 
(Kiyono et al., 2009; Jiang et al., 2016). Though much is known about starvation-induced 
autophagy, many aspects of TGFβ-induced autophagy have not yet been elucidated. It is 
of interest to assess whether knockdown of p62 or p62-associated proteins would alter 
autophagy, and to determine whether TGFβ-dependent autophagy may have a 
relationship with TGFβ-dependent EMT. 
Alongside autophagy, p62 has been shown to act as a signaling hub in the mTORC1, 
NFκB, and Nrf2 pathways (Moscat et al., 2016). It remains unknown whether p62 has a 
role in TGFβ signaling, however, p62 does associate with key TGFβ signaling proteins: 
aPKC via its PB1 domain and TRAF6 via its TRAF6-binding domain (Katsuragi et al., 
2015). Because of these interactions, it is plausible that p62 affects TGFβ signaling. 
Previous studies from our lab have shown that aPKC alters canonical TGFβ signaling 
(Gunaratne et al., 2015), but it is unknown whether p62 may regulate aPKC activity. 
Since both TRAF6 and aPKC independently form complexes with TGFβRs, p62 may 
also co-localize with TGFβ receptors.  
Based on the aforementioned rationale, I hypothesize that p62 regulates TGFβ-dependent 
EMT and autophagy. To test this, aims of this thesis were (Fig. 1.5): 
1.  Assess effect of p62 silencing on canonical TGFβ signaling and EMT. 
2.  Assess p62 and p62-associated protein (aPKC and TRAF6) silencing on TGFβ-
dependent autophagy. 
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Figure 1.5. 
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Figure 1.5. Thesis Aims 
These aims are based on both aspects of p62: its role in autophagy and its role in 
signaling. The first aim will assess if p62 is required for TGFβ-dependent Smad 
phosphorylation and EMT, and the second will assess if p62 and p62-associated proteins 
are required for TGFβ-induced autophagy.  
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Chapter 2 : Materials and Methods  
 Antibodies and reagents 2.1.
All antibodies, sources, applications and working dilutions are provided in Table 2.1.  
Table 2.1. Antibodies 
 Antibody Company Product # Application Dilution  
E-Cadherin 
BD 
Biosciences  610182 Immunoblotting 1:1000 
EEA1  
BD 
Biosciences  610457 Immunoblotting 1:1000 
Flag 
Sigma-
Aldrich 
F3165 
Immunoprecipitation 
1 µg/ 1 mg 
protein 
Immunoblotting  1:1000 
GAPDH 
Cell 
Signaling  
  
2118 Immunoblotting 1:2000 
HA (Y-11) Santa Cruz  sc-805 Immunofluorescence 1:300 
Lamin A/C Santa Cruz  sc-6125 Immunoblotting 1:1000 
LC3B  
Cell 
Signaling  2775 Immunoblotting  1:1000 
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Mouse from donkey 
Alexafluor 488 Invitrogen A21202 Immunofluorescence 1:250 
Mouse from donkey 
Alexafluor 647  Invitrogen A21236 Immunofluorescence 1:250 
Mouse from goat HRP  eBioscience  
18-8817-
31 Immunoblotting 1:25000 
N-Cadherin 
BD 
Biosciences  610921 Immunoblotting 1:1000 
p62 (SQSTM1)  
Cell 
Signaling   5114 Immunoblotting 1:1000 
p62 (SQSTM1)  Abnova 
 H000088
78-M01 Immunoprecipitation  
1 µg/ 1 mg 
protein 
Phospho-Smad2  
Cell 
Signaling  3101 Immunoblotting 
1:1000 in 
5% skim 
milk 
PKC iota (H-76) Santa Cruz sc-11399 Immunoblotting 1:1000 
Rab7  Santa Cruz sc-376362 Immunofluorescence 1:100 
Rabbit from donkey 
Alexafluor 488 Invitrogen A21206 Immunofluorescence 1:250 
Rabbit from donkey 
Alexafluor 647 Jackson 
711-605-
152 Immunofluorescence 1:250 
Rabbit from goat HRP Invitrogen PI31460 Immunoblotting 1:25000 
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Smad 2/3 
BD 
Biosciences  610843 Immunoblotting  1:1000 
TGFβ receptor II 
(C16) Santa Cruz  sc-220 Immunoblotting 1:1000 
TRAF6 
Cell 
Signaling  8082S Immunoblotting 1:1000 
Tubulin Sigma T4026 Immunoblotting 1:1000 
 
All reagents, sources, applications and working dilutions are provided in Table 2.2.  
Table 2.2. Reagents 
Reagent Company Product # Application Dilution 
Clarity Western ECL 
Substrate BioRad  170-5060 Immunoblotting  
As per 
manufacturer’s 
protocol 
DCTM Protein Assay  
(Reagent S) 
(Reagent A) 
(Reagent B) BioRad  
 500-
(0115) 
(0113) 
(0114)  Protein assay 
As per 
manufacturer’s 
protocol  
Dyngo-4a Abcam Ab120689 Dynamin inhibition 10-50 µM 
G Sepharose   GE 
17-0618-
01 Immunoprecipitation 
100 µL 10% 
beads per IP 
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NE-PER® Nuclear 
and Cytoplasmic 
Extraction Reagents 
Thermo 
Fisher 
Scientific  78833 Nuclear fractionation  
N/A 
(manufacturer's 
protocol)  
Phalloidin Alexafluor 
555 Invitrogen A34055 Immunofluorescence  1:100 
RNA iMAX 
lipofectamine  
Thermo 
Fisher 
Scientific  
 13778-
150 
 Transfection 
(knockdown) 
 As per 
manufacturer’s 
protocol 
SiRNA Control  Invitrogen 4390844 Transfection 
N/A (varies per 
experiment) 
SiRNA towards p62 Invitrogen  s16960 Transfection 5 nM 
SiRNA towards PKC 
iota  Invitrogen  7945276 Transfection 37.5 nM 
SiRNA towards PKC 
zeta  Invitrogen  8740313 Transfection 75 nM 
SiRNA towards 
TRAF6 Invitrogen  s14389 Transfection 15 nM 
SuperSignalTM West 
Dura Extended 
Duration Substrate 
Thermo 
Fisher 
Scientific   34076  Immunoblotting 
 As per 
manufacturer’s 
protocol 
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 Cell Culture and transfections 2.2.
2.2.1. Cell culture 
A549 non-small cell lung cancer (NSCLC) cells were cultured in Nutrient Mixture F-12 
Ham Kaighn’s Modification (F12K; Sigma: N3520) supplemented with 10% fetal bovine 
serum (FBS). Mv1Lu mink lung cells stably transfected with HA-tagged TβRII were 
cultured in Minimal Essential Medium (MEM) supplemented with 1% non-essential 
amino acids, 0.3 mg/mL hygromycin and 10% FBS. All cell lines were kept in a cell 
culture incubator that was maintained at 37°C and had a high-humidity atmosphere 
composed of 5% CO2.  
2.2.2. Transfection 
The following transfection protocol describes RNA silencing in A549 cells. Twenty-four 
hours prior to transfection, 175 000 A549 cells were plated per well of a 6-well dish. 
Knockdown was carried out using Lipofectamine RNAiMAX Reagent (Table 2.2) as per 
manufacturer’s protocol. Briefly, appropriate amount of RNAiMAX was diluted in opti-
MEM and left to incubate for 5 minutes. In a separate tube, appropriate amount of siRNA 
was diluted in opti-MEM medium. RNAiMAX solution was then added to each siRNA 
solution (the volume of both solutions were equal). After gentle mixture by inversion, the 
mixture was left to incubate for 15 minutes. The solution was then added drop-wise onto 
the cells. Concentrations of siRNA towards their respective proteins were used as 
follows: 5 nM for siRNA directed to p62, 37.5 nM for siRNA directed to PKCι, 75 nM 
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for siRNA directed to PKCζ, and 15 nM for siRNA directed toward TRAF6. Cells were 
processed 48 hours post-transfection.  
 Cell lysis and protein isolation 2.3.
2.3.1.  Cell lysis, protein isolation and measurement for immunoblotting 
To isolate protein, cells were first washed with cold phosphate buffered saline (PBS). 
Lysis buffer (50 mM Tris pH 7.5, 1 mM EDTA, 0.5% TX-100, 150 mM sodium chloride, 
1 mg/mL pepstatin, 50 µM PMSF, 2.5 mM sodium fluoride, and 10 mM sodium 
pyrophosphate phosphatase inhibitor) was then put on the cells and left to incubate on a 
rocker at 4°C for 20 minutes. Cells were then scraped off the plate using cell scrapers and 
the lysate was then transferred to a 1.5 mL tube. Samples were centrifuged at 21 000 x g 
for 10 minutes at 4°C. After transferring the supernatant to a new tube and discarding the 
cell pellet, the lysates were stored at -20°C until use.  
2.3.2. Protein assay 
Cell lysate protein concentrations were measured according to the Lowry method (Fisher) 
prior to the addition of sample preparation buffer. Protein assays were carried out using 
the DCTM Protein Assay (Table 2.2) as per manufacturer’s protocol. Absorbance was 
measured using a Beckman Coulter DU730 spectrometer or a PerkinElmer Victor 3V 
Multi-Detection Microplate Reader.  
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 Nuclear fractionation 2.4.
Nuclear fractionation was done using NE-PERTM Nuclear and Cytoplasmic Extraction 
Reagents (Table 2.2) as per the manufacturer’s protocol, and as described in Gunaratne 
et al., 2015. Briefly, cells were dissociated using trypsin, washed with PBS and pelleted.  
Cytoplasmic extraction reagents I and II were then added and samples were centrifuged 
(21 000 x g at 4˚C) to separate nuclear protein (cell pellet) from the cytoplasmic protein 
(supernatant). Nuclear extraction reagent was then added to the pellet, vortexed, and 
centrifuged again to isolate nuclear protein.  
 TGFβ treatment 2.5.
One day prior to TGFβ treatment, cells were washed once with PBS, then serum starved 
overnight using medium supplemented with 0.2% FBS. The following day, cells were 
treated with 250 pM of TGFβ unless otherwise stated (incubation time varies per 
experiment).  
For the 5-day TGFβ experiments, cells were serum starved for 4 hours one day post-
transfection, then treated with 250 pM TGFβ. For each day of the experiment, cells were 
thoroughly washed with PBS to remove cellular debris and then replaced with fresh 
medium supplemented with 0.2% FBS and 250 pM TGFβ.  
 SDS-PAGE and immunoblotting 2.6.
In preparation for immunoblotting, sample preparation buffer (30% glycerol, 10% 1.5 M 
Tris (pH 6.8), 1.2% SDS, 0.018% bromophenol blue, and 15% β-mercaptoethanol) was 
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added to lysates, and then the samples were boiled at 100°C for 5 minutes before being 
subjected to SDS-PAGE. Cell lysates were subjected to gel electrophoresis (SDS-PAGE) 
using a stacking gel composed of 5% acrylamide and a separating gel composed of 10% 
acrylamide. For the 5-day TGFβ experiment, samples were run on a 15% acrylamide gel 
to ensure proper separation of LC3BI from LC3BII protein.  A range of 50-100 µg of 
protein per sample was loaded into the gel, which was run at a constant 200 V. Proteins 
were then transferred onto a nitrocellulose membrane via wet transfer (Biorad), which 
was maintained at a cold temperature by using ice packs. After protein transfer, staining 
was done using Ponseau S (15% acetic acid; 4 mg/mL Ponseau S). Ponseau S was 
washed off the membranes using tris-buffered saline-tween 20 (TBST; 50 mM Tris, 150 
mM NaCl, 0.05% Tween-20, pH 7.5). Membranes were then blocked with 5% skim milk 
diluted in TBST for 1 hour, rocking at room temperature. Primary antibodies diluted in 
TBST (dilutions for each antibody are shown in Table 2.2) were then left on the 
membranes to incubate overnight, rocking at 4°C. The following day, the membranes 
were washed three times with TBST, each wash being 10 minutes in duration rocking at 
room temperature. Membranes were then incubated with the appropriate HRP-conjugated 
secondary antibody diluted in TBST for 1 hour at room temperature. Following 
secondary antibody incubation, membranes were washed three more times (10 minutes 
each). Excess TBST was then drained from the membranes and, using a pipette, 
membranes were washed several times with enhanced chemiluminescent substrate (Table 
2.2).  Visualization was carried out using a Bio-Rad Versa-doc Imager and 
QuantityOne® 1-D Analysis software. Quantitation/densitometry was done using the 
volume tools within the QuantityOne® 1-D Analysis software.  
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 Antibody feeding/TGFβ receptor internalization analysis 2.7.
Colocalization of TβRII with p62 and rab7 was done using Mv1Lu mink lung cells that 
were stably transfected to over express pMEP4 with cDNA encoding HA-tagged TβRII 
under a zinc-inducible promoter (Di Guglielmo et al., 2003; Gunaratne et al., 2012). One 
day after being plated on coverslips, cells were serum starved overnight using medium 
supplemented with 0.2% FBS and 50 µM zinc chloride. The following day, cells were 
placed on ice for 5 minutes to interrupt receptor trafficking. Primary anti-HA antibody 
(1:250) was diluted in 0.2% FBS medium and left to incubate on the cells for 2 hours on 
ice. The coverslips were washed 3 times with PBS, and then appropriate AlexaFluorTM-
conjugated secondary antibody was added and left to incubate on ice for 1 hour in the 
dark. Coverslips were washed another 3 times with PBS before being put back to 37°C at 
various times to induce trafficking. At the indicated times, coverslips were removed, 
fixed, and permeabilized (please refer to section 2.8 Immunofluorescence microscopy).  
 Immunofluorescence microscopy 2.8.
Coverslips were first washed one time with PBS, then fixed using 4% PFA (left to 
incubate for 10 minutes at room temperature). After another 3 PBS washes, cells were 
permeabilized by incubating coverslips in 0.25% Triton X-100 for 5 minutes. After 3 
PBS washes, coverslips were blocked using a 10% FBS solution diluted with PBS and 
left to rock at room temperature for 1 hour. The FBS solution was then aspirated and 300 
µL of appropriate primary antibody (diluted in 10% FBS solution as described in Table 
2.1) was immediately added to the coverslips. Primary antibody was left to incubate 
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overnight at 4°C on a rocker. The following day, coverslips were washed 3 times with 
PBS and appropriately diluted AlexafluorTM-conjugated antibody (please see Table 2.1) 
was left to incubate on coverslips for 1 hour at room temperature in the dark. After 
another 3 PBS washes, coverslips were incubated in DAPI solution (1:1000 dilution in 
PBS) for 5 minutes. After 1 PBS rinse, coverslips were mounted onto glass slides using 
liquid Immunomount (Fisher Scientific). Samples were left to dry in the dark overnight 
before visualization. If imaging was not done immediately, slides were stored in the dark 
at -20°C until use. 
Imaging of coverslips was done using an Olympus IX81 motorized inverted microscope 
and InVivo software.  
 Microarray: RNA quality assessment, probe preparation 2.9.
and GeneChip hybridization 
All GeneChips were processed at the London Regional Genomics Centre (Robarts 
Research Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA quality was 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) 
and the RNA 6000 Nano kit (Caliper Life Sciences, Mountain View, CA). Single 
stranded complimentary DNA (sscDNA) was prepared from 200 ng of total RNA as per 
the Ambion WT Expression Kit (Applied Biosystems, Carlsbad, CA) and the Affymetrix 
GeneChip WT Terminal Labeling kit and Hybridization User Manual (Affymetrix, Santa 
Clara, CA). Total RNA was first converted to cDNA, followed by in vitro transcription to 
make cRNA. Five micrograms of single stranded cDNA were synthesized, end labeled 
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and hybridized, for 16 hours at 45°C, to Human Gene 1.0 ST arrays. All liquid handling 
steps were performed by a GeneChip Fluidics Station 450 and GeneChips were scanned 
with the GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA) using Command 
Console v1.1. Probe level (.CEL file) data was generated using Affymetrix Command 
Console v1.1. Probes were summarized to gene level data in Partek Genomics Suite v6.5 
using the RMA algorithm adjusted for GC content (Irizarry et al., 2003). Using Partek, 
any batch affect due to scan date was removed and an ANOVA (Yijk = µ + Condition * 
Timeij+ eijk) using Method of Moments was run to determine gene level p-values. Fold 
change comparisons are expressed relative to untreated siControl cells, and represent the 
average of two separate experiments (2 separate gene chips per condition). A fold change 
of ± 1.7 was considered as the cutoff for induction. 
 Statistical Analysis 2.10.
All quantitation is representative of at least 3 replicates. Evaluation of results was done 
using a one-way or two-way ANOVA followed by a Bonferonni post-hoc test. These 
tests were carried out by using GraphPad Prism® Version 6 software. Values of p<0.05 
were considered statistically significant.   
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Chapter 3 : Results 
 P62 co-localizes with TβRII at the late endosome 3.1.
Previous studies have shown that aPKC has interactions with both p62 (Sanchez et al., 
1998) and TβRII (Gunaratne et al., 2013).  Furthermore, Dr. Gunaratne also observed that 
p62 interacts with TGFβ receptors (unpublished data; Appendix Fig. A1).  However, the 
subcellular location where this interaction may occur remained unknown.  Thus, I first 
investigated the temporal subcellular localization of p62 and TGFβ receptors using 
immunofluorescence microscopy (Fig. 3.1). 
Briefly, Mv1Lu cells stably transfected with extracellular HA-tagged TβRII were used to 
follow the internalization of cell surface labelled receptors in order to investigate whether 
they localize with p62/SQSTM1 during their trafficking from the cell surface to 
intracellular vesicles (Fig. 3.1).  Cell surface TβRII were labeled using anti-HA antibody 
and fluorescent secondary antibody at 4˚C (a temperature that does not permit vesicular 
trafficking) and the cells were then incubated at 37˚C (to reinitiate vesicular trafficking) 
for various amounts of time before fixing and counterstaining with either markers for the 
early (EEA1) or late (Rab7) endosomal compartments (please see Methods Section 2.7 & 
2.8).  As incubation time at 37˚C increases, TβRII signal gradually become more 
punctate, which is consistent with the internalization of the receptor. Indeed, I observed 
that after 1 hour of incubation at 37˚C, TGFβ receptors co-localized with EEA1, as 
previously reported (Fig 3.1A; Di Guglielmo et al., 2003). When counterstained with 
anti-Rab7, moderate co-localization with TβRII was observed at the 3-hour time point 
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(seen as a yellow signal; Fig. 3.1B). This indicates that the later trafficking of TβRII 
involves Rab7, and this agrees with previous studies (Balogh et al., 2015). 
Counterstaining with anti-p62 also shows moderate co-localization at the 3-hour time 
point (Fig. 3.1C). Taken together, my results suggest that there is a co-localization 
between p62 and TβRII at a time point when the TGFβ receptors arrive at the late 
endosome. 
 Receptor internalization is necessary for maximum Smad 3.2.
phosphorylation 
Since p62 associates with TGFβ receptors (Appendix; Fig. A1) and co-localizes with 
TβRII (Fig. 3.1), it has potential to affect the canonical TGFβ signaling pathway. In order 
to assess this, I investigated whether silencing p62 would alter the extent and time course 
of Smad2 phosphorylation and Smad2 nuclear translocation in response to TGFβ 
stimulation. Briefly, A549 cells were transfected with control siRNA or siRNA targeting 
p62 (Fig. 3.2A) and incubated with increasing concentrations (0-10 pM) of TGFβ.  
Following western blotting using phopho-specific Smad2 antibodies, I observed that p62 
silencing had no effect in the magnitude or duration of Smad2 phosphorylation at the 
various TGFβ concentrations (Fig. 3.2B). Furthermore, the presence or absence of p62 
did not affect the ability of TGFβ to stimulate Smad2 nuclear localization, as assessed by 
immunofluorescence microscopy (Fig. 3.2C).  In the absence of TGFβ, the Smad2 
immunofluorescence signal had the characteristic hazy cellular pattern, indicating that it 
is present in the entirety of the cell.  After TGFβ incubation, the Smad2 signal became  
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Figure 3.1A 
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Figure 3.1B 
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Figure 3.1C 
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Figure 3.1. Colocalization exists between TβRII and EEA1, between TβRII and 
Rab7, and between TβRII and p62     
Immunofluoresence microscopy was carried out using Mv1Lu mink lung epithelial cells 
stably transfected with HA-tagged TβRII. After serum starving overnight, cell surface 
receptors were labelled at 4˚C with anti-HA. Cells were then incubated at 37˚C for 
various times before fixing and counter staining with anti-EEA1 (A), anti-Rab7 (B), or 
anit-p62 (C) antibodies. Bar = 10 µm. Images represent n=3.  
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Figure 3.2 
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Figure 3.2. p62 knockdown does not affect Smad phosphorylation and translocation  
(A) 5 nM of siRNA towards p62 is sufficient to knockdown p62 protein levels. (B) A549 
NSCLC cells were transfected with the indicated siRNA and serum starved the next day 
overnight. 48 hours post-transfection, cells were then incubated with increasing amounts 
of TGFβ for 1 h. Total lysates were subjected to SDS-PAGE and immunoblotting. (C) 
A549 NSCLC cells were transfected with the indicated siRNA and serum-starved the 
next day overnight. 48 hours post-transfection, cells were incubated with 250 pM TGFβ 
for 1 h, then fixed, permeablized and stained for Smad2. Images represent n=3.  
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crisp and co-localized with the DAPI-stained nucleus, indicating nuclear translocation 
(Fig. 3.2C). The immunofluorescence micrographs containing the p62 knockdown 
condition appeared very similar to the control, indicating that silencing p62 did not affect 
Smad2 nuclear translocation (Fig. 3.2C).  
A potential reason for the lack of effect of p62 silencing on TGFβ dependent signal 
transduction could be that the interaction between p62 and TGFβ receptors occurs in the 
late endosome.  Indeed, TGFβ signaling has been shown to occur in the early endosomal 
compartment and therefore the signal transduction pathway is fully engaged by the time 
that the receptors access the p62-positive compartment.  In fact, previous studies have 
used Dynamin mutants to show that receptor internalization is necessary for the 
maximum phosphorylation of Smad (Di Guglielmo et al., 2003; Runyan et al., 2005). In 
order to test this in my cell system, I pharmacologically inhibited Dynamin activity, and 
by extension receptor endocytosis, using Dyngo-4a.  Using antibody feeding and 
immunofluorescence microscopy, I first established that Dyngo-4a was indeed inhibiting 
internalization of cell surface TGFβ receptors (Fig 3.3A). In control cells, the 
internalization of receptors was observed within 1 hour to result in a punctate, perinuclear 
TβRII stain that co-localized with EEA1 (a marker for the early endosome). Using these 
parameters, I observed that Dyngo4a retained immunofluorescent receptor signal at the 
cell surface, indicating that inhibition of dynamin blocked receptor internalization.  
I then assessed the effect of dynamin inhibition on Smad phosphorylation using western 
blotting (Fig 3.3B). A549 NSCLC cells were treated with increasing concentrations of 
Dyngo-4a in the presence or absence of TGFβ ligand for one hour and the cell lysates 
were then analyzed by immunoblotting. I observed that TGFβ-dependent Smad  
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Figure 3.3A 
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Figure 3.3B and 3.3C 
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Figure 3.3. Inhibition of receptor internalization by Dyngo-4a attenuates TGFβ-
dependent Smad phosphorylation 
(A) Immunofluoresence microscopy was carried out using Mv1Lu mink lung epithelial 
cells stably transfected with HA-tagged TβRII. After serum starving overnight, cell 
surface receptors were labelled at 4˚C with anti-HA. Cells were then incubated at 37˚C 
for various times before fixing and counter staining with anti-EEA1 antibody. Bar = 10 
µm. (B) A549 NSCLC cells were serum starved overnight and incubated with the 
increasing concentrations of Dyngo-4a for one hour. The cells were then incubated in the 
presence or absence of 250 pM TGFβ for one hour before lysing. Cell lysates were 
subjected to SDS-PAGE and immunoblotting using anti-Phospho-Smad2 and anti-Smad2 
antibodies. (C) Quantitation of P-Smad2 levels in conditions with TGFβ incubation. Bars 
labelled with uppercase letters are significantly different (p<0.05) from bars labelled with 
the same lowercase letter. Images represent n=3. 
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phosphorylation was significantly attenuated after incubation with 40 µM and 50 µM of 
Dyngo-4a (Fig 3.3C), which supports the notion that receptor signaling occurs during 
early events in receptor endocytosis and that access to the late endosomal compartment, 
where p62 resides, occurs after signal transduction is initiated.  
 TGFβ reduces levels of nuclear p62 3.3.
Although I observed that p62 silencing did not appear to alter Smad2 nuclear 
translocation (Fig. 3.2C), I further investigated this using a quantitative method. Briefly, 
A549 cells were transfected with control siRNA or siRNA targeted towards p62, 
incubated with TGFβ for 30 minutes, washed, then further incubated for either 2.5 or 5.5 
hours before lysis and subcellular fractionation. Cytoplasmic and nuclear fractions were 
isolated and subjected to immunoblotting (Fig. 3.4A). Consistent with my 
immunofluorescence microscopy analysis, there were no significant differences observed 
in the time course of nuclear Smad2 localization (Fig. 3.4B). 
As a parallel study, I also investigated the levels of nuclear p62, as the nucleocytoplasmic 
shuttling of p62 has been reported to occur in response to autophagy (Pankiv et al., 
2010).  Since TGFβ has been shown to also induce autophagy (Kiyono et al., 2009; Ding 
& Choi, 2014; Jiang et al., 2016), I assessed if the amount of nuclear p62 would change 
in response to TGFβ treatment (Fig. 3.4A).  Interestingly, nuclear p62 appeared as a 
doublet in the sip62 condition, which may be indicative of post-translational 
modifications. Furthermore, the amount of p62 observed in the nucleus of control cells 
decreased significantly in response to TGFβ treatment (Fig. 3.4C).   
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Figure 3.4. p62 knockdown does not affect Smad2 translocation. TGFβ reduces the 
amount of nuclear p62 
(A) A549 NSCLC cells were transfected with the indicated siRNA and then serum 
starved the next day. 48 hours post-transfection, cells were incubated with 250 pM TGFβ 
for 30 minutes, washed, and then further incubated for 2.5 or 5.5 h before lysis and 
fractionation. Cytoplasmic and nuclear fractions were then subjected to SDS-PAGE and 
immunoblotting. P62 knockdown did not affect nuclear Smad2 levels (B), however, 
nuclear p62 levels decreased in SiControl cells, 3 hours after the start of the TGFβ 
treatment (C). Images represent n=3. 
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 P62 knockdown reduces basal E-cadherin and induces 3.4.
preliminary stress fibres in NSCLC cells 
Nucleocytoplasmic shuttling of p62 has been proposed to affect the ubiquitination and 
degradation of transcription factors, some of which are involved in EMT (Bertrand et al., 
2015; Grassi et al., 2015).  Since I observed that TGFβ reduced the levels of nuclear p62, 
it was of interest to explore whether p62 knockdown would have an effect on TGFβ-
dependent EMT. TGFβ-induced EMT involves a reduction in epithelial cell markers (for 
e.g., E-cadherin) and an induction of mesenchymal cell markers (for e.g., N-cadherin).  I 
therefore assessed E- and N-cadherin proteins levels after incubation with TGFβ ligand. 
Briefly, A549 cells were transfected with control siRNA or siRNA targeted towards p62, 
incubated with TGFβ for 24 or 48 hours and subjected to immunoblotting (Fig. 3.5A).  I 
observed that TGFβ induced a robust loss of E-cadherin and an increase in N-cadherin 
levels as previously described by our laboratory (Fig. 3.5A; Gunaratne et al., 2013).  
Interestingly, this cadherin switch was very similar in control and p62-silenced cells; 
however, it was observed that basal levels of E-cadherin in p62-silenced cells were 
significantly lower compared to control (Fig. 3.5B). This suggests that knockdown of p62 
may prime cells to undergo EMT. Furthermore, I observed that p62 levels were also 
significantly attenuated by incubation with TGFβ for 24 or 48 hours (Fig. 3.5D). In order 
to further assess if p62 silencing would prime A549 cells to undergo EMT, I carried out 
microarray studies. 
Microarray analysis was used as a method to identify possible alterations in gene 
expression after silencing p62. Results could potentially explain how p62 silencing 
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Figure 3.5 
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Figure 3.5. p62 knockdown reduces basal E-cadherin levels in a TGFβ-independent 
manner 
(A) A549 NSCLC cells were transfected with the indicated siRNA and serum starved the 
next day. 48 hours after transfection, cells were then incubated with 250 pM TGFβ for 0, 
24, or 48 hours. Total cell lysates were subjected to SDS-PAGE and immunoblotting. (B) 
TGFβ induces a reduction in E-cadherin levels at the same rate between the control and 
p62 knockdown conditions, however, p62 knockdown reduced the basal level of E-
cadherin. No differences were observed in N-cadherin induction between control and 
p62-silenced cells. Levels of p62 were also significantly attenuated after incubation with 
TGFβ for 24 or 48 hours. Images represent n=3.  
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attenuates levels of basal E-cadherin expression (Fig. 3.5). To conduct this experiment, 
A549 cells were transfected with either control siRNA or siRNA towards p62. Forty-
eight hours post-transfection, total RNA was extracted and submitted to the London 
Regional Genomics Centre for microarray analysis. After normalization (please refer to 
Methods section 2.9), results were processed and summarized (Table A1). In support of 
my immunoblotting findings, p62 silencing attenuated the transcription of E-cadherin 
(CDH1) but did not affect the relative levels of N-cadherin (CHD2) transcript levels. 
To further my analyses, I next assessed the structure of the actin cytoskeleton, as it also 
realigns from the cell cortex into stress fibers in cells undergoing EMT (Thiery, 2002; 
Lamouille et al., 2014).  Using phalloidin, which stains for filamentous actin, I analyzed 
the effects of p62 knockdown on TGFβ-dependent EMT by immunofluorescence 
microscopy (Fig. 3.6). The control cells contained cortical actin organization in the 
absence of TGFβ, but robust stress fibers in cells that were incubated with TGFβ for 48 
hours (Fig. 3.6A). Interestingly, the silencing of p62 induced the formation of 
preliminary stress fibres, even in the absence of any TGFβ induction (Fig. 3.6B). 
However, after the addition of TGFβ ligand, the stress fibre formation did not appear to 
be different between the siControl and sip62 cells, consistent with my findings that once 
EMT is initiated, the TGFβ effect supercedes the effects of p62. Taken together, these 
results suggest that the presence of p62 may maintain cells in a more epithelial state and 
that removal of p62, either by siRNA or TGFβ, supports EMT. 
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Figure 3.6. p62 knockdown induces preliminary formation of actin stress fibres 
(A) A549 cells were transfected with either control siRNA or siRNA towards p62. After 
serum starving overnight, cells were then incubated in the presence or absence of TGFβ 
for 48 h. Cells were then fixed, permeabilized, and stained for p62 and filamentous actin. 
Bar=10 µm. (B) In each replicate, 10 images were taken and the longest stress fibre and 
shortest cell axis from three cells per image were measured blindly. The values presented 
represent the average length of the longest stress fibres relative to the shortest axis within 
the same cell. Bars labelled with uppercase letters are significantly different (p<0.05) 
from bars labelled with the same lowercase letter. Images represent n=3. 
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 P62 in TGFβ-induced autophagy 3.5.
Recent findings show that sustained TGFβ treatment induces autophagy (Jiang et al., 
2016).  Since proteins that are involved in TGFβ signaling, namely aPKC and TRAF6, 
also associate with p62, I next investigated if the presence or absence of these proteins 
would affect TGFβ-dependent autophagy.  I therefore silenced p62, aPKC or TRAF6 and 
assessed LC3BII protein levels, as the conversion of LC3BI to LC3BII is a marker of 
autophagy. Briefly, A549 cells were transfected with control siRNA or siRNA targeting 
p62, aPKC or TRAF6 and incubated in the presence (Fig. 3.7) or absence (Fig. 3.8) of 
TGFβ for 0 to 5 days. Total cell lysates were subjected to immunoblotting for EMT (E-
cadherin, N-cadherin) or autophagic  (LC3BII) markers.  I observed that cells expressing 
control siRNA contained elevated LC3BII levels in response to TGFβ over the time 
course of the experiment (Fig. 3.8B). Interestingly, TRAF6 levels were also observed to 
be significantly higher after incubation with TGFβ (Fig. 3.8C).  
Knockdown of aPKC appeared to moderately hinder TGFβ-dependent induction of 
autophagy, whereas TRAF6 silencing was observed to have a slightly more dramatic 
effect (Fig 3.8B). Indeed, the levels of TRAF6 protein appear to parallel those of LC3BII, 
indicating that it has potential to serve as a novel marker for TGFβ-dependent autophagy. 
With respect to EMT, aPKC knockdown was also seen to inhibit this process —
specifically the cadherin switch (Fig 3.7A). This effect was previously observed by our 
lab (Gunaratne et al., 2013). Additionally, in the absence of TGFβ, p62 knockdown  
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Figure 3.7 
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Figure 3.7. Autophagy is induced by sustained TGFβ treatment 
(A) A549 NSCLC cells were transfected with the indicated siRNA. 24 hours post-
transfection, cells were incubated with 0.2% serum medium and treated with 250 pM 
TGFβ for 0 to 5 days. Cells were washed and medium/TGFβ ligand was replaced every 
day they were in culture. Total cell lysates were then subjected to SDS-PAGE and 
immunoblotting. An increase in LC3BII protein levels is indicative of autophagy 
induction. (B) Quantitation shows a significant reduction in TGFβ-dependent LC3BII 
induction after silencing aPKC or TRAF6. (C) In the presence of TGFβ, quantitation of 
TRAF6 levels shows a similar trend of induction relative to LC3BII levels. Bars labelled 
with uppercase letters are significantly different (p<0.05) from bars labelled with the 
same lowercase letter. Images represent n=3.  
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 Figure 3.8 
A) 
A) 
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Figure 3.8. Effect of different knockdowns and sustained incubation in serum-
starved medium 
(A) A549 NSCLC cells were transfected with the indicated siRNA. 24 hours post-
transfection, cells were incubated with 0.2% serum medium for 0 to 5 days. Cells were 
washed and medium was replaced every day they were in culture. Total cell lysates were 
then subjected to SDS-PAGE and immunoblotting. (B) LC3BII induction is dependent on 
the presence of TGFβ ligand. (C) TRAF6 induction is dependent on the presence of 
TGFβ ligand. (D) Silencing p62 attenuates the rise in E-cadherin levels after 2 and 3 days 
in culture. Bars labelled with uppercase letters are significantly different (p<0.05) from 
bars labelled with the same lowercase letter. Images represent n=3.  
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appears to attenuate the rise in E-cadherin levels, thus further supporting my findings 
above (Fig. 3.8D). 
 Knockdown of aPKC (but not p62 or TRAF6) attenuates 3.6.
Smad phosphorylation 
Since TRAF6 levels were seen to parallel levels of inducted LC3BII, it was important to 
investigate whether TRAF6 would have an effect on canonical TGFβ signaling. I 
therefore investigated the extent and duration of Smad phosphorylation in cells with 
TRAF6 knockdown, and compared this to the effects of aPKC and p62 knockdown (Fig 
3.9). Briefly, A549 cells were transfected with the indicated siRNAs (Fig. 3.9C), and 
incubated with TGFβ for 30 minutes, washed, then further incubated for either 1 or 4 
hours (Fig. 3.9A). Total lysates were then subjected to immunoblotting. In control cells, I 
observed that the time course of Smad2 phosphorylation was highest after 30 min of 
incubation and decreased thereafter (Fig. 3.9) I also observed that aPKC knockdown (but 
not p62 or TRAF6 knockdown) attenuated the amount of Smad phosphorylation at all 
time points post-incubation with TGFβ (Fig. 3.9B). This supports our previous findings 
that show an attenuation of Smad2 nuclear translocation, as well as attenuation of the 
EMT cadherin switch after aPKC knockdown (Gunaratne et al., 2015). Interestingly 
however, since TRAF6 silencing did not affect TGFβ-dependent Smad2 phosphorylation 
but did inhibit TGFβ-dependent autophagy, this suggests that TRAF6 is downstream of 
(or parallel to) the TGFβ signaling pathway during autophagy. 
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Figure 3.9 
 
 
A) 
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Figure 3.9. aPKC knockdown attenuates Smad phosphorylation  
(A) A549 NSCLC cells were transfected with the indicated siRNA and serum starved the 
next day. 48 hours post-transfection, cells were then incubated with 250 pM of TGFβ for 
30 minutes, washed, and then further incubated for 1 or 4 h before lysis. Lysates were 
then subjected to SDS-PAGE and immunoblotting. aPKC knockdown attenuated Smad 
phosphorylation (B). Bars labelled with uppercase letters are significantly different 
(p<0.05) from bars labelled with the same lowercase letter. (C) Knockdown efficiency of 
p62, aPKC, and TRAF6 at 0 h. Images represent n=3.  
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Taken together, my results suggest that p62 may prime cells to undergo TGFβ-dependent 
EMT and efficient autophagy and future studies analyzing the mechanism(s) will be of 
great interest. 
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Chapter 4 : Discussion  
 Summary and general discussion 4.1.
Several cancer types (including non-small cell lung cancer) are able to evade the tumor 
suppressive components of TGFβ while keeping its signaling intact. Thus, it is important 
to characterize TGFβ regulated processes within this context. The present study is the 
first to explore the role of the p62 protein in canonical TGFβ signaling as well as in 
TGFβ-dependent autophagy. Here we suggest that silencing p62 does not affect canonical 
TGFβ signaling through Smads, however, nuclear p62 levels appear to be responsive to 
TGFβ. In addition, knockdown of p62 appears to prime NSCLC cells for TGFβ-induced 
E-cadherin loss but also hinders the progression of TGFβ-induced autophagic processes. 
Furthermore, knockdown of the p62 and TGFβ receptor associated proteins aPKC and 
TRAF6 also hinder TGFβ-induced autophagy, as assessed by the conversion of LC3BI to 
LC3BII.   
 p62 localizes with TβRII at the late endosome 4.2.
Previous studies from our lab have shown that aPKC is an important regulator of TGFβ 
signaling (Gunaratne et al., 2012, 2013, 2015). As a binding partner to aPKC, p62 has 
potential in modulating the activity of aPKC. Although previous studies suggest that p62 
is not capable of altering the kinase activity of aPKC (Moscat et al., 2007), it is still 
capable of regulating activity via scaffolding or degradation. Since aPKC has been shown 
to associate with the TGFβ receptors (Gunaratne et al., 2013), I first decided to test  
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Figure 4.1. Thesis general summary 
(A) These conclusions are based on both aspects of p62: its role in autophagy and its role 
in signaling. The first conclusion is that p62 is required attenuates EMT processes in a 
Smad-independent manner, and the second is that p62 is promotes TGFβ-induced 
autophagic processes. Additional observations include the involvement of aPKC in 
promoting both EMT and autophagic processes, and the promotion of TGFβ-dependent 
autophagic LC3BII induction by TRAF6. (B) Two models describing the EMT-
autophagy relationship that are supported by the data. The first model shows EMT 
induction leading to autophagy, and the second portrays EMT and autophagy as 
independent processes.  
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 whether p62 would also co-localize to TβRII. Using stably transfected cells 
overexpressing HA-tagged TβRII, we observed that after 3 hours of internalization, 
TβRII localizes to Rab7 positive endosomes (Fig. 3.1B). Since TβRII co-localizes to p62 
at the same time point (Fig. 3.1C), this suggests that TβRII and p62 are found together at 
the late endosome. This notion is further supported by previous studies that show co-
localization between p62 and Rab7 (Sanchez et al., 1998). Further, preliminary co-
immunoprecipitation studies show a direct association between p62 and TβRII 
(Appendix; Fig. A1). This finding implicates possible roles of p62 in the regulation of 
TGFβ signaling, possibly through the autophagic degradation of the type II receptor. 
Indeed, previous studies suggest that p62 facilitates lysosomal degradation of aPKC 
(Sanchez et al., 1998), so it remains plausible that the type II receptor is also anchored to 
lysosome-targeted endosomes via p62.  
 p62 and TRAF6 do not affect canonical TGFβ signaling 4.3.
Due to its localization with TβRII and its potential in modulating aPKC activity, I 
investigated whether p62 affects canonical Smad signaling through siRNA-mediated 
silencing. In my studies I found that knockdown of p62 does not affect the magnitude of 
Smad2 phosphorylation, the nuclear translocation of Smad2, as well as the length of time 
Smad2 spends in the nucleus. This can be explained by temporal differences between the 
transduction of the canonical signaling pathway and the association of p62 with the type 
II receptor (as explained above). Since Smad phosphorylation maximally occurs at the 
early endosome (Fig. 3.3; Runyan et al., 2005) and p62 does not co-localize with the 
receptors until they reach the late endosome, the silencing of p62 expression may only 
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have effects on signaling events downstream of Smad phosphorylation. Indeed, other 
proteins that are known to regulate Smad phosphorylation such as SARA and endofin are 
found in early endosomes (Chen, 2009).  
This finding also suggests that p62 is not critical for the scaffolding of aPKC to proteins 
relevant to the canonical signaling pathway. Although previous studies have found that 
p62 mediates the lysosomal degradation of aPKC (Sanchez et al., 1998), it is possible 
that aPKC can be degraded by other means, such as proteasomal degradation. It is also 
possible that p62 may regulate atypical TGFβ signaling that is relevant to EMT, such as 
the TRAF6 or Par6 pathways. Since aPKC has been shown to regulate both of these 
pathways (Gunaratne et al., 2013, 2015) and p62 binds both aPKC and TRAF6 (Puissant 
et al., 2012; Katsuragi et al., 2015), there is potential for p62 to be involved in non-
canonical TGFβ signaling pathways. 
 The status of p62 as a tumor promoter vs. tumor 4.4.
suppressor 
It is clear that p62 is involved in tumorigenesis, as several studies show that its 
expression is abnormal in various cancer types, including lung (Inoue et al., 2012), 
ovarian (Iwadate et al., 2014), breast (Yuan & Xi, 2013), and prostate (Kitamura et al., 
2006). In my investigations involving the silencing of p62 expression, I have found that 
p62 initiates E-cadherin loss (Fig. 3.5), as well as the preliminary formation of stress 
fibers (Fig. 3.6), suggesting that p62 has a tumor suppressor status in A549 lung 
adenocarcinoma cells. This, however, appears to be independent of canonical TGFβ 
signaling (Fig. 3.2 & 3.4; Discussion section 4.2). The literature suggests that this 
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classification is heavily context-dependent, and many factors can influence how p62 acts 
in tumorigenesis (Linares et al., 2011; Moscat & Diaz-Meco, 2012; Puissant et al., 2012). 
Some of these factors include cell phenotype (i.e. epithelial vs. stromal cells), the stage of 
the tumor, p62 cellular localization, and possibly even the phosphorylation of p62. p62 is 
also involved in both tumor suppressing and tumor promoting pathways, which also 
indicates dependence on signaling crosstalk (reviewed in Puissant et al., 2012).  
4.4.1. The effect of cell phenotype on p62 status 
The first factor that may affect the tumor suppressor/promoter status of p62 is cell 
phenotype and signaling. In an investigation done in hepatocarcinoma cells (HCCs) by 
Umemura et al., 2016, p62 was identified as a tumor promoter since ectopic expression 
of p62 in neoplastic livers was able to initiate tumorigenesis. This effect was attributed to 
the activation of mTORC1 and Nrf2, which support the survival of hepatocarcinoma 
progenitor cells by preventing the accumulation of reactive oxygen species (ROS). In 
contrast, an earlier study done by Valencia et al., 2014 showed that p62 expression has 
tumor suppressive effects in the stromal cells that support HCC. This characterization 
was also attributed to p62’s regulation of mTORC1—lower p62 levels would cause less 
mTORC1 activation and the accumulation of ROS, which then initiates the release of IL-
6, and subsequently, TGFβ. In more recent studies, Duran et al., 2016 identified p62 as a 
mediator of vitamin D tumor suppression which occurs through the inhibition of Smad3-
DNA binding. Taken together, these studies suggest a tumor-promoting role of p62 in 
hepatocarcinoma cells, and a tumor-suppressing role in hepatic stromal cells. In relation 
to my investigations, A549 NSCLC cells appear to be more similar to the stromal 
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phenotype. In support of this, previous studies have identified a mutation in the A549 cell 
line of the Nrf2-inhibitor, Keap1 (Singh et al., 2006), rendering it dysfunctional. This 
then suggests that p62 would not affect the already over-active Nrf2, since p62 was 
shown to act by inhibiting and sequestering Keap1. It would be interesting to further 
investigate TGFβ ligand secretion from p62-silenced A549 cells, as well as the effects of 
vitamin D release as a possible mechanism to explain the loss of basal E-cadherin 
expression (Fig. 3.5) and preliminary stress fiber formation (Fig. 3.6).  
4.4.2. Cell signaling pathways and p62 status 
As previously mentioned, the attenuation of E-cadherin expression by p62 knockdown is 
independent of canonical TGFβ signaling (Fig. 3.2 & 3.4), and could possibly be 
explained by regulation of the atypical TGFβ pathways. There are, however, other 
signaling pathways that control EMT processes and the expression of E-cadherin, such as 
the Wnt pathway. p62 is capable of regulating Wnt signaling by degrading the protein 
Dishevelled (Dvl; Gao et al., 2010). After the activation of Wnt signaling, Dsh acts to 
promote the nuclear translocation of the β-catenin, which binds other transcription factors 
and recruits other co-factors in a complex that has been shown to up-regulate the 
expression of Snail and Twist (Howe et al., 2003; Derk ten et al., 2008). Thus, the 
silencing of p62 expression would attenuate Dvl degradation and promote downstream 
Wnt signaling and EMT processes. A recent study done in A549 cells shows that 
activation of Wnt down-regulates the expression of E-cadherin in a β-catenin-dependent 
manner (Song et al., 2015), therefore, regulation of Wnt signaling remains a possible 
explanation for my observations after p62 knockdown. Since there is also crosstalk 
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between the Wnt and TGFβ signaling pathways, a third possibility remains in which p62 
regulates both pathways such that the end result is a down regulation of basal E-cadherin 
expression.  
Another major tumorigenic signaling pathway in which p62 is involved is the NFκB 
pathway (Diaz-Meco & Moscat, 2012). Although previously described in a context 
related to Paget’s disease and the formation of the ternary complex with aPKC and 
TRAF6 (Introduction Section 1.5.3), p62 has also been shown to regulate Ras-induced 
NFκB signaling. In a study done by Duran et al., 2008, it was shown that p62 expression 
was up-regulated and required for Ras-induced NFκB signaling and subsequent 
tumorigenesis. Ras is also interrelated to TGFβ signaling, as well as the conduction of 
EMT processes and the expression of Snail (Horiguchi et al., 2009; Kim et al., 2014; 
Saitoh et al., 2016). Since p62 was characterized as a tumor promoter in the study done 
by Duran et al., this aspect of Ras cell signaling deserves further exploration in the A549 
cell model to elucidate possible discrepancies in signaling. Indeed, the role of p62 in Ras 
signalling appears to be complex, as our microarray data (Table A1) show that silencing 
p62 down-regulates the expression of Ras-related proteins that both inhibit (Rab1b; Jiang 
et al., 2015) and promote (Rab22a; Su et al., 2016) tumorigenesis. Furthermore, crosstalk 
between TGFβ and Ras could also be investigated.  
4.4.3. Tumor stage and p62 status 
Numerous studies agree that the accumulation of p62 is conducive to tumorigenesis in 
preneoplastic tissues (Duran et al., 2008; Inoue et al., 2012; Iwadate et al., 2014). 
Previous studies have shown that silencing p62 expression in A549 cells appears to 
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inhibit cell proliferation and growth of the primary tumor (Nihira et al., 2014), but in my 
studies, I have observed that it may be conducive to migratory processes. This can be 
explained by the autophagy paradox. At early stages in carcinogenesis, dysfunctional 
autophagic processes lead to the accumulation of p62 and potential mutagens. 
Conversely, autophagy (and the degradation of p62) is able to sustain tumor cell survival 
and promote metastasis once tumors are established.  Thus, it is important to consider the 
stage of the tumor in the deliberation of whether p62 supports or opposes cancer 
progression. Ellis et al., 2014 showed that localized melanoma development correlated 
with higher levels of p62, however, this expression significantly declined when observing 
metastatic stage III/IV tumors. Furthermore, patients with “low p62” tumors had higher 
incidences of metastatic lesions with reduced disease free survival over a period of 7 
years. Therefore, although p62 accumulation can support initial tumor establishment and 
localized growth, it may inhibit the metastasis of more advanced cancers.  
4.4.4. Phosphorylation status and nuclear localization of p62 
Phosphorylation status is another aspect of p62 that can regulate its behaviour in tumor 
progression vs. suppression. p62 phosphorylation has been shown to be important in 
autophagy induction (Matsumoto et al., 2011) as well as p62-mediated regulation of cell 
signaling (Katsuragi et al., 2015). Further, phosphorylation of p62 has also been 
implicated in the management of appropriate mitotic transitions. Expression of 
unphosphorylatable p62 promoted faster proliferation and greater tumor establishment of 
Ras-transformed cells (Linares et al., 2011). 
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Phosphorylation also modulates the nucleocytoplasmic shuttling of p62, specifically at a 
site near its second (more downstream) nuclear localization signal (Pankiv et al., 2010). 
This is also meaningful in the context of tumorigenesis: several studies suggest that 
cytoplasmic p62 levels serves as a prognostic marker for more aggressive ovarian 
(Iwadate et al., 2014), oral squamous cell (Liu et al., 2014), and prostate (Kitamura et al., 
2006) tumors. The function of nuclear p62 is still not well understood, however, a recent 
study shows that p62 regulates histone ubiquitination and response to DNA damage by 
directly associating with RNF168 (Wang et al., 2016). Autophagy deficiency-induced 
accumulation of p62 in the nucleus inhibits RNF168 and impedes its function towards 
DNA damage repair.  
Interestingly, I observed a decrease in nuclear p62 levels in response to TGFβ ligand 
(Fig. 3.4), which could potentially be accredited to a change in a phosphorylation status, 
although I did not assess this. This result agrees with the tumorigenic profile of TGFβ 
signaling in cancer cells, since lower nuclear p62 correlates cancer aggressiveness and 
metastasis (Iwadate et al., 2014). It would be interesting to explore whether DNA damage 
repair by RNF168 is activated by lower nuclear p62 induced by TGFβ.  
 TRAF6 is important in TGFβ-dependent autophagy  4.5.
Prolonged incubation of A549 cells induced autophagy induction (Fig. 3.7 & 3.8), as 
measured by the induction of LC3BII levels. Knockdown of either aPKC or TRAF6, but 
not p62, appeared to attenuate LC3BII induction (Fig. 3.7). A possible explanation for 
why p62-associated proteins (as opposed to p62) are required for TGFβ-dependent 
autophagy is because of functionally redundant proteins of p62, such as neighbour of 
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BRCA1 gene 1 (NBR1). Due to its structural similarity, NBR1 is also capable of 
selectively targeting ubiquitinated cargo to autophagosomes via LC3B association 
(Komatsu & Ichimura, 2010). Thus, even after silencing p62 expression, the induction of 
LC3BII by TGFβ may occur since NBR1 is still being expressed. Outside the context of 
autophagy, however, NBR1 lacks many functional domains that p62 uses to regulate 
signaling (Bitto et al., 2014).  
This study is the first to identify potential involvement of aPKC and TRAF6 in 
autophagy, and it would be of great interest to elucidate how these proteins might 
regulate this process. I observed that TRAF6 levels appear to follow that of LC3BII (Fig. 
3.7), indicating that it may serve as a novel marker for autophagy.  
 Relationship between EMT and autophagy 4.6.
Due to its apparent complexity, several models have arisen to explain the relationship 
between EMT and autophagy. It has been proposed that EMT is inhibited by autophagy, 
that autophagy induces EMT, that EMT induces autophagy, and that EMT and autophagy 
are independent processes (reviewed in Gugnoni et al., 2016). By observing both EMT 
and autophagy, the present study provides temporal evidence that supports 2 models: 
EMT processes (i.e. the cadherin switch) induce autophagic processes (i.e. induction of 
LC3BII protein), and EMT processes and autophagic processes are independent of each 
other (Fig. 4.1B). However, it is important to note that there is much left unknown about 
TGFβ-induced autophagy. Nutrient-stress-induced autophagy may share a different 
relationship with EMT than that of TGFβ-induced autophagy, and further investigations 
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should be directed towards identifying differences in how autophagy is induced in these 
two contexts.  
Additionally, the EMT-autophagy relationship may also be dependent on cell type, tumor 
stage, and other contextual factors.   
 Limitations and future directions 4.7.
All of these studies were conducted in established cell lines, and this is the major 
limitation of my investigation.  It would be interesting to repeat these experiments in an 
in vivo model, or perhaps using human tumor samples. Further, stable protein 
overexpression in mink lung cells was used to observe co-localization due to the inability 
to detect such low endogenous levels of TβRII in other cell lines through 
immunofluorescence microscopy. A caveat of overexpression studies includes the 
possibility of falsely positive associations, since some proteins form aggregates and 
inorganic structures once transfected.  
In these studies, several cellular processes were determined using protein markers. 
Firstly, TGFβ signalling was assessed by measuring Smad2 phosphorylation. This, 
however, neglects other downstream TGFβ signalling events, which include the 
production of PAI-1 and the secretion of fibronectin. A similar limitation exists in the 
assessment of EMT, which was done using E-cadherin and N-cadherin protein markers. 
Use of additional mesenchymal protein markers, such as vimentin, would strengthen my 
current observations. Lastly, autophagy was assessed by observing the conversion of 
LC3BI to LC3BII. This is correlative with autophagosome formation, and visual methods 
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of assessment (such as electron microscopy and immunofluorescence microscopy) would 
bolster my findings.  
It would be very interesting to further investigate the mechanism and consequence of 
TGFβ-attenuated nuclear p62 levels. Recent studies have shown that p62 associates with 
transcription factors SNAIL and TWIST (Qiang et al., 2014; Grassi et al., 2015), which 
are both regulated under TGFβ, and may provide a link between p62 silencing and EMT 
processes. Additional studies using nuclear export mutants or Leptomycin B could be 
done to shed light on the effects of nuclear p62. Since p62 was observed to co-localize 
with TβRII (Fig 3.1C), p62 may also potentially affect the half-life of TGFβ receptors. 
Furthermore, p62 may also have effects on non-canonical TGFβ pathways (and 
subsequent EMT), but this remains unexplored. Lastly, in order to further explore the 
TGFβ-dependent EMT-autophagy relationship, it would be interesting to observe the 
effects of autophagy inhibition on EMT. This could be done either by the use of 3-
methyladenine or by the knockdown of autophagy-dependent proteins like Atg5, 7, or 
Beclin1. 
 Significance 4.8.
TGFβ regulates EMT and autophagy, both of which are relevant to metastasis and tumor 
progression. In the present study, I have investigated both TGFβ-dependent EMT and 
autophagy in lung adenocarcinoma through a study of the p62 protein. This research 
proposes that p62 attenuates EMT processes but is necessary for autophagy induction. 
These effects, however, appear to be Smad-independent. Interestingly, both nuclear and 
total p62 protein levels are reduced in response to TGFβ ligand. Taken together, we have 
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found that p62 acts to suppress EMT processes in NSCLC. Although its involvement in 
carcinogenesis is apparent, p62 is a multifunctional protein and is also involved in other 
processes like autophagy. As such, the consideration of p62 as a potential therapeutic 
target is complex. Additional studies on the consequences TGFβ-dependent autophagy 
will be necessary to fully characterize the tumor promoting vs. suppressive status of p62.    
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Figure A1. TβRII associates with p62 
HEK 293T cells were transfected with cDNA encoding HA-tagged TGFβ type II receptor 
(HA-TβRII), Flag-tagged type I TGFβ receptor (Flag-TβRI), HA-tagged p62 and/or Flag-
tagged Par6 as indicated. Cells were then lysed and immunoprecipitated (IP) using anti 
(α)-TβRII antibodies. The immunoprecipitates were immunoblotted with anti-Flag and 
anti-HA antibodies to visualize immunoprecipitated Flag-tagged TβRI and Par6, HA-
tagged TβRII and p62 (top panel). Cell lysates were also immunoblotted with anti-Flag 
and anti-HA antibodies to visualize relative protein expression.  This unpublished figure 
was used with permission from Dr. Adrian Gunaratne. 
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Table A1 
 
Gene Assignment  
Gene 
Symbol 
Fold Change (sip62 vs. 
siControl) 
NM_001122665 //  DEAD (Asp-Glu-Ala-Asp) box helicase 
3, Y-linked DDX3Y 2.40847 
NM_001080431 // solute carrier family 45, member 4  SLC45A4 2.39626 
NM_000245 // MET proto-oncogene, receptor tyrosine 
kinase MET 2.22943 
NM_001102614 // solute carrier family 35, member G6 SLC35G6 2.18439 
NM_021101 //  claudin 1 CLDN1 2.01194 
NM_006931 // solute carrier family 2 (facilitated glucose 
transporter), member SLC2A3 1.99991 
NM_001281435 //  mitogen-activated protein kinase kinase 
4  MAP2K4 1.91443 
NM_013348 // potassium channel, inwardly rectifying 
subfamily J, member 14 KCNJ14 1.88735 
NR_030364 // microRNA 634  MIR634 1.85684 
NM_003812 // ADAM metallopeptidase domain 23  ADAM23 1.8277 
NM_001136017 // cyclin D3  CCND3 1.76997 
NM_198541 // IGF like family member 1 IGFL1 1.72548 
NM_198541 // IGF like family member 1 IGFL1 1.72548 
NM_173515 // CNKSR family member 3 CNKSR3 -1.73402 
NM_001289095 // PX domain containing serine/threonine 
kinase PXK -1.78328 
NM_004170 // solute carrier family 1  SLC1A1 -1.79028 
NM_001303130 // growth arrest-specific 2 like 3 GAS2L3 -1.80136 
NM_004360 // cadherin 1, type 1  CDH1 -1.84322 
NM_001311197 // relaxin 3  RLN3 -1.86307 
NM_001243120 // S-phase kinase-associated protein 2, E3 
ubiquitin protein ligase SKP2 -1.93945 
NM_000112 // solute carrier family 26 (anion exchanger), 
member 2  SLC26A2 -1.95497 
NM_001193533 //  NIMA-related kinase 4 NEK4 -1.95642 
NM_030981 // RAB1B, member RAS oncogene family RAB1B -1.98488 
NM_180989 // G protein-coupled receptor 180 GPR180 -2.0107 
NM_001252148 // solute carrier family 39, member 9  SLC39A9 -2.05715 
NM_001127383 // cytochrome b reductase 1 CYBRD1 -2.13444 
NM_001285387 //  THO complex 7 THOC7 -2.18039 
NM_024103 // solute carrier family 25 (mitochondrial 
carrier; phosphate carrier) 
SLC25A2
3 -2.21596 
NM_020673 // RAB22A, member RAS oncogene family  RAB22A -2.39946 
NM_001164232 // DDHD domain containing 2  DDHD2 -2.41008 
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Table A1. Knockdown of p62 alters gene expression by microarray analysis  
A549 NSCLC cells were transfected with either control siRNA or siRNA directed toward 
p62. Forty-eight hours post-transfection, total RNA was extracted and subjected to 
microarray analysis. Fold change comparisons are shown as relative differences of the 
sip62 condition when compared to siControl. Highlighted genes are relevant to 
characterize the role of p62 in carcinogenesis. Table represents n=2. 
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